The efficacy of DNA methylation inhibitor decitabine plus the cytidine deaminase inhibitor cedazuridine in the treatment of MDS and chronic myelomonocytic leukemia was demonstrated in the recent clinical studies of ASTX727-01-B and ASTX727-02 and they were approved by the United States Food and Drug Administration [3,4,5]. This evidence concerns the gene CDA and myelodysplastic syndrome.